Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2020-11-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于本次非公开发行不存在直接或通过利益相关方向发行对象提供财务资助或补偿的承诺
Regulatory Filings Classification · 95% confidence The document is a short announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding a commitment that there is no financial assistance or compensation provided to related parties in connection with a non-public share issuance. It references compliance with specific regulatory rules about non-public stock issuance. The document length is only 552 characters, indicating it is a brief announcement rather than a full report. There is no financial data, detailed analysis, or comprehensive report content. It is not a full capital/financing update report but rather a regulatory compliance statement related to financing activities. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS) rather than a Capital/Financing Update (CAP) or other categories. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-11-26 Chinese
关于公司非公开发行股票申请文件反馈意见的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to feedback from the China Securities Regulatory Commission regarding a non-public stock issuance application by Shenzhen Haier Bioengineering Co., Ltd. It includes extensive disclosures about the subscription object, funding sources, compliance with securities laws, administrative penalties during the reporting period, and corrective measures taken. The content focuses on regulatory compliance, legal and financial due diligence, and detailed explanations related to a capital raising event (non-public stock issuance). This aligns with a Capital/Financing Update (CAP) filing, as it provides updates on the company's fundraising activities and related regulatory feedback and responses. The document is lengthy (15,000 characters) and contains substantive content, not merely an announcement or certification, so it is not an RPA or RNS. It is not an Annual Report, Audit Report, or other categories related to financial results or governance changes. Therefore, the best classification is Capital/Financing Update (CAP).
2020-11-26 Chinese
关于收到《中国证监会行政许可项目审查一次反馈意见通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (724 characters) from a company regarding receipt of a regulatory feedback notice from the China Securities Regulatory Commission (CSRC) about their non-public stock issuance application. It states the company will respond and disclose further information later. There are no financial statements or detailed financial data, only a regulatory update about the approval process and associated risks. The document is not a full report but a regulatory announcement about an ongoing administrative review. According to the rules, such regulatory announcements that do not contain financial data or detailed report content should be classified as Regulatory Filings (RNS).
2020-11-16 Chinese
监事会关于第八届监事会第九次会议相关事项的审核意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's review opinion on matters discussed in a specific meeting of the supervisory board of Shenzhen Haier Bioengineering Co., Ltd. It discusses compliance with regulatory guidelines and the extension of commitments by the controlling shareholder. The document is short (455 characters) and does not contain financial statements or detailed financial data. It is not an annual report, audit report, or financial report. It is also not a voting result announcement or a management change notice. The content is related to regulatory compliance and supervisory board opinions, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2020-11-13 Chinese
关于召开2020年第四次临时股东大会通知的公告
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2020 fourth extraordinary general meeting of shareholders of Shenzhen Haiwang Bioengineering Co., Ltd. It includes information about the meeting time, location, agenda items, voting procedures, registration methods, and proxy authorization. There are no financial statements or financial performance data presented. The document is an announcement of a shareholders' meeting, not a report or transcript. It is not a voting results declaration since it is a notice before the meeting. Therefore, the document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or related to the Annual General Meeting or other shareholder meetings.
2020-11-13 Chinese
独立董事关于第八届董事局第十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a board meeting matter, specifically about the progress and extension of a commitment by the controlling shareholder. It references regulatory guidelines and corporate governance rules but does not contain financial statements or detailed financial data. The document is short (527 characters) and is a formal opinion related to board matters rather than a full report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters.
2020-11-13 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.